Figure S7.

SARS-CoV-2-Specific MBCs Can Express Neutralizing Antibodies, Related to Figure 4 and Table S1

(A) Gating strategy for sorting RBD-specific B cells.

(B) IgG ELISA to confirm expression of Visit 1 antibodies in transfected cell culture supernatants. Positive control is the kit standard (std) and negative control is supernatant from untransfected cells (no trans, green).

(C) RBD ELISA of purified Visit 1 monoclonal antibodies. Negative control (green) is an irrelevant Plasmodium-specific antibody.

(D) IgG ELISA to confirm expression of Visit 2 antibodies in transfected cell culture supernatants.

(E) RBD ELISA of purified Visit 2 monoclonal antibodies.

(F) Number of mutations in variable regions of RBD-specific monoclonal antibodies.

(G) Mutation frequency of variable regions of RBD-specific monoclonal antibodies.

Statistics determined by two-tailed Mann-Whitney tests. Multiple testing correction significance cutoff at FDR = 0.05 is p value < 0.05.